免疫治疗时代下肿瘤疗效的评价标准

doi:10.3760/cma.j.issn.1673-422X.2018.06.009

摘要/Abstract

摘要： 随着免疫治疗时代的到来以及多种非常规缓解模式如延迟反应、假性进展的出现，多种免疫相关疗效评价标准如免疫相关疗效标准、实体肿瘤免疫相关疗效评价标准、实体肿瘤免疫疗效评价标准等标准相继被提出。这些标准的评价原则和判定结果与传统疗效评价标准存在很大差异，尤其是最新提出的实体肿瘤免疫疗效评价标准，引入待证实的疾病进展和已证实的疾病进展两个新概念，为实体肿瘤提供了一种全新的疗效评价模式，有望为肿瘤免疫治疗时代下一些亟待解决的临床问题提出解决方案。

关键词: 肿瘤, 免疫治疗, 疗效评价, 实体肿瘤免疫疗效评价标准

Abstract: With the advent of the times of immunotherapy and the emergence of a variety of unconventional response patterns such as delayed response and pseudoprogressive disease, a variety of immunerelated efficacy evaluation criteria such as immunerelated response criteria, immunerelated response evaluation criteria in solid tumor and immune response evaluation criteria in solid tumor have been proposed successively. The evaluation principles and judgment results of these criteria are distinctly different from the traditional response evaluation criteria. In particular, the newly proposed immune response evaluation criteria in solid tumor introduces two new concepts of unconfirmed progressive disease and confirmed progressive disease and provides a new response evaluation model for solid tumors, which is expected to provide solutions to some of the most urgent clinical problems under the times of cancer immunotherapy.

Key words: Neoplasms, Immunotherapy, Response evaluation, Immune response evaluation criteria in solid tumors

白日兰，郭寒菲，崔久嵬. 免疫治疗时代下肿瘤疗效的评价标准[J]. 国际肿瘤学杂志, 2018, 45(6): 358-361.

Bai Rilan, Guo Hanfei, Cui Jiuwei. Evaluation criteria for tumor efficacy in the times of immunotherapy[J]. Journal of International Oncology, 2018, 45(6): 358-361.

参考文献

［1］ Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated nonsmallcell lung cancer (OAK): a phase 3, openlabel, multicentre randomised controlled trial［J］. Lancet, 2017, 389(10066): 255-265. DOI: 10.1016/S0140-6736(16)32517-X. ［2］ Rosenberg JE, HoffmanCensits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinumbased chemotherapy: a singlearm, multicentre, phase 2 trial［J］. Lancet, 2016, 387(10031): 1909-1920. DOI: 10.1016/S0140-6736(16)00561-4. ［3］ Hui R, Garon EB, Goldman JW, et al. Pembrolizumab as firstline therapy for patients with PDL1positive advanced nonsmall cell lung cancer: a phase 1 trial［J］. Ann Oncol, 2017, 28(4): 874-881. DOI: 10.1093/annonc/mdx008. ［4］ Carlino MS, Long GV. Ipilimumab combined with nivolumab: a standard of care for the treatment of advanced melanoma?［J］. Clin Cancer Res, 2016, 22(16): 3992-3998. DOI: 10.1158/10780432.CCR-15-2944. ［5］ Chiou VL, Burotto M. Pseudoprogression and immunerelated response in solid tumors［J］. J Clin Oncol, 2015, 33(31): 3541-3543. DOI: 10.1200/JCO.2015.61.6870. ［6］ Tarhini AA. Tremelimumab: a review of development to date in solid tumors［J］. Immunotherapy, 2013, 5(3): 215-229. DOI: 10.2217/imt.13.9. ［7］ Wolchok JD, Hoos A, O′day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria［J］. Clin Cancer Res, 2009, 15(23): 7412-7420. DOI: 10.1158/1078-0432.CCR-09-1624. ［8］ Nishino M, Gargano M, Suda M, et al. Optimizing immunerelated tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?［J］. J Immunoth Cancer, 2014, 2: 17. DOI: 10.1186/2051-1426-2-17. ［9］ Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics［J］. Lancet Oncol, 2017, 18(3): E143-152. DOI: 10.1016/S1470-2045(17)30074-8. ［10］ Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment［J］. Cancer, 1981, 47(1): 207-214. ［11］ Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada［J］. J Natl Cancer Inst, 2000, 92(3): 205216. ［12］ Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)［J］. Eur J Cancer, 2009, 45(2): 228-247. DOI: 10.1016/j.ejca.2008.10.026. ［13］ Fabel M, Wulff A, Heckel F, et al. Clinical lymph node staginginfluence of slice thickness and reconstruction kernel on volumetry and RECIST measurements［J］. Eur J Radiol, 2012, 81(11): 3124-3130. DOI: 10.1016/j.ejrad.2012.03.008. ［14］ Kwak JJ, Tirumani SH, Van den Abbeele AD, et al. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immunerelated adverse events［J］. Radiographics, 2015, 35(2): 424-437. DOI: 10.1148/rg.352140121. ［15］ Weiss J, Notohamiprodjo M, Bedke J, et al. Imaging response assessment of immunotherapy in patients with renal cell and urothelial carcinoma［J］. Curr Opin Urol, 2018, 28(1): 3541. DOI: 10.1097/MOU.0000000000000463. ［16］ Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an antiPD1 immune checkpoint inhibitor, for patients with advanced, refractory squamous nonsmallcell lung cancer (CheckMate 063): a phase 2, singlearm trial［J］. Lancet Oncol, 2015, 16(3): 257-265. DOI: 10.1016/S1470-2045(15)70054-9. ［17］ Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of immunerelated response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab［J］ . J Clin Oncol, 2016, 34(13): 1510-1517. DOI: 10.1200/JCO.2015.64.0391. ［18］ Carter CA, Schmitz B, Peterson PG, et al. Immune reactivity and pseudoprogression or tumor flare in a serially biopsied neuroendocrine patient treated with the epigenetic agent RRx001［J］. Case Rep Oncol, 2016, 9(1): 164-170. DOI: 10.1159/000444633. ［19］ Cohen JV, Alomari AK, Vortmeyer AO, et al. Melanoma brain metastasis pseudoprogression after pembrolizumab treatment［J］. Cancer Immunol Res, 2016, 4(3): 179-182. DOI: 10.1158/2326-6066.CIR-15-0160. ［20］ Bayo Calero J, Avió Tarazona V. A rapid response to pembrolizumab in a patient with metastatic melanoma［J］. Immunotherapy, 2017, 9(3): 225-228. DOI: 10.2217/imt-2016-0136. ［21］ Iijima Y, Hirotsu Y, Amemiya K, et al. Very early response of circulating tumourderived DNA in plasma predicts efficacy of nivolumab treatment in patients with nonsmall cell lung cancer［J］. Eur J Cancer, 2017, 86: 349357. DOI: 10.1016/j.ejca.2017.09.004. ［22］ Sanmamed MF, PerezGracia JL, Schalper KA, et al. Changes in serum interleukin8 (IL8) levels reflect and predict response to antiPD-1 treatment in melanoma and nonsmallcell lung cancer patients［J］. Ann Oncol, 2017, 28(8): 1988-1995. DOI: 10.1093/annonc/mdx190. ［23］ Nishino M, GiobbieHurder A, Manos MP, et al. Immunerelated tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions［J］. Clin Cancer Res, 2017, 23(16): 4671-4679. DOI: 10.1158/1078-0432.CCR-17-0114. ［24］ Tazdait M, Mezquita L, Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD1 or PDL1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria［J］. Eur J Cancer, 2018, 88: 38-47. DOI: 10.1016/j.ejca.2017.10.017. ［25］ Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by antiPD1/PDL1［J］. Clin Cancer Res, 2017, 23(8): 1920-1928. DOI: 10.1158/1078-0432.CCR-16-1741. ［26］ Nishino M, Jagannathan JP, Krajewski KM, et al. Personalized tumor response assessment in the era of molecular medicine: cancerspecific and therapyspecific response criteria to complement pitfalls of RECIST［J］. AJR Am J Roentgenol, 2012, 198(4): 737-745. DOI: 10.2214/AJR.11.7483. ［27］ Nishino M, GiobbieHurder A, Gargano M, et al. Developing a common language for tumor response to immunotherapy: immunerelated response criteria using unidimensional measurements［J］. Clin Cancer Res, 2013, 19(14): 3936-3943. DOI: 10.1158/10780432.CCR-13-0895. ［28］ Reck M, RodriguezAbreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PDL1positive nonsmallcell lung cancer［J］. N Engl J Med, 2016, 375(19): 1823-1833. DOI: 10.1056/NEJMoa1606774.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.